Aryx Therapeutics OTC Pink Sheet Insiders


USD 0.0005  0.00  0.00%   

Aryx Therapeutics employes about 56 people. The company is managed by 4 executives with total tenure of roughly 67 years, averaging almost 16.0 years of service per executive having 14.0 employees per reported executive. Break down of Aryx Therapeutics management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Aryx Therapeutics future performance.
Please continue to Trending Equities.
  Paul Goddard  Chairman
Chairman and CEO

Aryx Therapeutics Management Team Effectiveness

Aryx Therapeutics has return on total asset (ROA) of (74.86) % which means that it has lost $74.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (13243.0) %, meaning that it created substantial loss on money invested by shareholders. Aryx Therapeutics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Aryx Therapeutics Workforce Comparison

Aryx Therapeutics I is number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—Specialty & Generic industry is presently estimated at about 119,556. Aryx Therapeutics adds roughly 56.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.

Aryx Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aryx Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aryx Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aryx Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Aryx Therapeutics Benchmark Summation

The output start index for this execution was zero with a total number of output elements of five hundred fourteen. Aryx Therapeutics Price Series Summation is a cross summation of Aryx Therapeutics price series and its benchmark/peer.

Aryx Therapeutics Notable Stakeholders

An Aryx Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aryx Therapeutics often face trade-offs trying to please all of them. Aryx Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aryx Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Paul Goddard - Chairman and CEOProfile
John Varian - COOProfile
Nicholas Simon - DirectorProfile
David Nagler - VP of Corporate Affairs and SecretaryProfile

About Aryx Therapeutics Management Performance

The success or failure of an entity such as Aryx Therapeutics often depends on how effective the management is. Aryx Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aryx Therapeutics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aryx Therapeutics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.
The data published in Aryx Therapeutics' official financial statements usually reflect Aryx Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Aryx Therapeutics. For example, before you start analyzing numbers published by Aryx Therapeutics accountants, it's critical to develop an understanding of what Aryx Therapeutics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Aryx Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aryx Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Aryx Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aryx Therapeutics I. Please utilize our Beneish M Score to check the likelihood of Aryx Therapeutics' management to manipulate its earnings.

Aryx Therapeutics Workforce Analysis

Traditionally, organizations such as Aryx Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aryx Therapeutics within its industry.

Aryx Therapeutics Manpower Efficiency

Return on Aryx Therapeutics Manpower

Revenue Per Employee352.2 K
Revenue Per Executive4.9 M
Net Loss Per Employee327.3 K
Net Loss Per Executive4.6 M
Working Capital Per Employee2.2 K
Working Capital Per Executive31.5 K
Please continue to Trending Equities. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for analysis

When running Aryx Therapeutics price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Please note, there is a significant difference between Aryx Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aryx Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aryx Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.